HOME Top Market Reports Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020

Biosimulation Market by Product (Software, Molecular Modeling, PB/PK, PKPD, Trial Design, Toxicity Prediction, In-house, Contract Service), Application (Drug Discovery & Development, Preclinical, Clinical Trial) & by End Users - Global Forecast to 2020

By: marketsandmarkets.com
Publishing Date: July 2015
Report Code: HIT 3629

 

  Speak to Analyst Enquiry Before Buying  
purchase report
download pdf  request for customisation


The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, at a CAGR of 15.29%. Biosimulation refers to the modeling and simulation of complex biological processes and systems to understand their functions and physiologies at the molecular level. Biosimulation is used for target identification & validation, lead discovery & optimization, preclinical testing and clinical trials. This market report studies the potential of biosimulation software and services in drug discovery and development.

The major drivers for the market include the strong trend of R&D investments in biotechnology and pharmaceutical industries; the need to curtail drug discovery & development costs; growth in the biologics and biosimilars market; increased use of personalized medicines; technological advancements; and the trend of periodic product upgradation.

In this report, the global biosimulation market is segmented based on product, application, end user, and geography. By product, the market includes software and services. The software segment includes molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, trail design software, toxicity prediction software, and other software (QSP, visualizing and analytical software). The services segment includes in-house services and external/contract services.

Based on applications, the market is segmented into drug discovery, drug development, and others (defense, industrial bioprocessing, nutraceuticals, and agri-food production). The drug development application segment is further classified into preclinical testing and clinical trials. The drug discovery segment is divided into target identification & validation and lead identification & optimization. The end users for this market are academic and government research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users (defense, nutraceuticals companies, and food and agricultural companies).

Based on geography, the market is segmented into North America, Europe, Asia, and the Rest of the World (RoW).

The major players in the global biosimulation market are Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systθmes SA (France), Schrφdinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland).

Scope of the Report

This report categorizes the global biosimulation market into the following segments and subsegments:

Global Biosimulation Market, by Product

  • Software
    • PK/PD Modeling and Simulation Software
    • Molecular Modeling and Simulation Software
    • PBPK Modeling and Simulation Software
    • Toxicity Prediction Software
    • Trial Design Software
    • Other Software (QSP, Visualizing and Analytical Software)
  • Services
    • In-house Services
    • External/Contract Services

Global Biosimulation Market, by Application

  • Drug Development
    • Preclinical Testing
      • ADME/Tox
      • PK/PD
    • Clinical Trials
  • Drug Discovery
    • Lead Identification and Optimization
    • Target Identification and Optimization
  • Other Applications

Global Biosimulation Market, by End User

  • Academic and Government Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Contract Research Organization
  • Regulatory Authorities
  • Other End Users

Global Biosimulation Market, by Geography

  • North America
  • Europe
  • Asia
  • Rest of the World

Table of Contents

1 Introduction (Page No. - 15)
    1.1 Objectives of the Study
    1.2 Market Definition
           1.2.1 Markets Covered
           1.2.2 Years Considered for the Study
    1.3 Currency
    1.4 Stakeholders

2 Research Methodology (Page No. - 17)
    2.1 Market Size Estimation
    2.2 Market Breakdown and Data Triangulation
    2.3 Market Share Estimation
           2.3.1 Key Data From Secondary Sources
           2.3.2 Key Data From Primary Sources
           2.3.3 Assumptions for the Study

3 Executive Summary (Page No. - 24)

4 Premium Insights (Page No. - 28)
    4.1 Lucrative Opportunities in the Global Biosimulation Market
    4.2 Life Cycle Analysis, By Region (2015–2020)

5 Market Overview (Page No. - 32)
    5.1 Introduction
    5.2 Market Segmentation
           5.2.1 By Product
           5.2.2 By Application
           5.2.3 By End User
    5.3 Market Dynamics
           5.3.1 Drivers
                    5.3.1.1 Growth in the Pharmaceutical and Biotechnology Industries
                    5.3.1.2 Increase in R&D Investments in the Pharmaceutical and Biotechnology Industries
                    5.3.1.3 Technological Advancements
                    5.3.1.4 Need to Curtail Drug Discovery and Development Costs
                    5.3.1.5 Growth in the Biologics and Biosimilars Market and Increased Use of Personalized Medicines
           5.3.2 Restraints
                    5.3.2.1 Lack of Standardization
                    5.3.2.2 Lack of Trained Professionals
           5.3.3 Opportunities
                    5.3.3.1 Emerging Applications
           5.3.4 Challenges
                    5.3.4.1 Limited Knowledge of Biological Systems and Processes
           5.3.5 Trends
                    5.3.5.1 Collaborations of Universities and Research Labs With Suppliers

6 Biosimulation Market, By Product (Page No. - 42)
    6.1 Introduction
    6.2 Software
           6.2.1 PK/PD Modeling and Simulation Software
           6.2.2 Molecular Modeling and Simulation Software
           6.2.3 Pbpk Modeling and Simulation Software
           6.2.4 Toxicity Prediction Software
           6.2.5 Trial Design Software
           6.2.6 Other Software
    6.3 Services
           6.3.1 In-House Services
           6.3.2 External/Contract Services

7 Biosimulation Market, By Application (Page No. - 55)
    7.1 Introduction
    7.2 Drug Development
           7.2.1 Preclinical Testing
                    7.2.1.1 PK/PD
                    7.2.1.2 ADME/TOX
           7.2.2 Clinical Trials
    7.3 Drug Discovery
           7.3.1 Target Identification and Validation
           7.3.2 Lead Identification and Optimization
    7.4 Other Applications

8 Biosimulation Market, By End User (Page No. - 70)
    8.1 Introduction
    8.2 Pharmaceutical and Biotechnology Companies
    8.3 Academic and Government Research Institutes
    8.4 Contract Research Organizations
    8.5 Regulatory Authorities
    8.6 Other End Users

9 Global Biosimulation Market, By Region (Page No. - 81)
    9.1 Introduction
    9.2 North America
    9.3 Europe
    9.4 Asia
    9.5 Rest of the World (RoW)

10 Competitive Landscape (Page No. - 108)
     10.1 Introduction
     10.2 Strategic Overview
     10.3 Leading Players in the Biosimulation Market
     10.4 Competitive Situation and Trends
             10.4.1 Product Upgradation
             10.4.2 Agreements, Collaborations, Expansions, and Partnerships
             10.4.3 New Product and Service Launches
             10.4.4 Acquisitions
             10.4.5 Other Developments

11 Company Profiles (Page No. - 116)
     11.1 Introduction
     11.2 Certara USA, Inc.
             11.2.1 Business Overview
             11.2.2 Products Offered
             11.2.3 Recent Developments
             11.2.4 MnM View
     11.3 Simulation Plus Inc.
             11.3.1 Business Overview
             11.3.2 Products Offered
             11.3.3 Recent Developments
             11.3.4 MnM View
     11.4 Dassault Systθmes SA
             11.4.1 Business Overview
             11.4.2 Products Offered
             11.4.3 Recent Developments
             11.4.4 MnM View
     11.5 Schrφdinger Inc.
             11.5.1 Business Overview
             11.5.2 Products Offered
             11.5.3 Recent Developments
             11.5.4 MnM View
     11.6 Advanced Chemistry Development, Inc.
             11.6.1 Business Overview
             11.6.2 Products Offered
             11.6.3 Recent Developments
             11.6.4 MnM View
     11.7 Chemical Computing Group, Inc.
             11.7.1 Business Overview
             11.7.2 Products Offered
             11.7.3 Recent Developments
             11.7.4 MnM View
     11.8 Entelos Holding Corporation
             11.8.1 Business Overview
             11.8.2 Products Offered
             11.8.3 Recent Developments
             11.8.4 MnM View
     11.9 Genedata Ag
             11.9.1 Business Overview
             11.9.2 Products Offered
             11.9.3 Recent Developments
             11.9.4 MnM View
     11.10 Physiomics PLC
             11.10.1 Business Overview
             11.10.2 Products Offered
             11.10.3 Recent Developments
             11.10.4 MnM View
     11.11 Rhenovia Pharma Ltd.
             11.11.1 Business Overview
             11.11.2 Products Offered
             11.11.3 Recent Developments
             11.11.4 MnM View

12 Appendix (Page No. - 135)
     12.1 Insights of Industry Experts
     12.2 Discussion Guide
     12.3 Other Developments
     12.4 Introducing RT: Real-Time Market Intelligence
     12.5 Available Customizations
     12.6 Related Reports


List of Tables (75 Tables)

Table 1 Market Summary of Biosimulation
Table 2 Growth in the Pharmaceutical and Biotechnology Industries Along With Increase in R&D Investments in These Industries is Propelling the Growth of the Biosimulation Market
Table 3 Lack of Standardization to Restrict Market Growth of Biosimulation
Table 4 Emerging Applications Present Significant Growth Opportunities for the Biosimulation Market
Table 5 Limited Knowledge of Biological Systems and Processes Pose A Challenge for the Biosimulation Market
Table 6 Collaborations of Universities and Research Labs With Suppliers is A Major Trend Observed in This Market
Table 7 Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 8 Biosimulation Software Market Size, By Type, 2013–2020 (USD Million)
Table 9 Biosimulation Software Market Size, By Region, 2013–2020 (USD Million)
Table 10 Biosimulation Market Size for PK/PD Modeling and Simulation Software, By Region, 2013–2020 (USD Million)
Table 11 Biosimulation Market Size for Molecular Modeling and Simulation Software, By Region, 2013–2020 (USD Million
Table 12 Biosimulation Market Size for Pbpk Modeling and Simulation Software, By Region, 2013–2020 (USD Million)
Table 13 Biosimulation Market Size for Toxicity Prediction Software, By Region, 2013–2020 (USD Million)
Table 14 Biosimulation Market Size for Trial Design Software, By Region, 2013–2020 (USD Million)
Table 15 Biosimulation Market Size for Other Software, By Region, 2013–2020 (USD Million)
Table 16 Biosimulation Services Market Size, By Type, 2013–2020 (USD Million)
Table 17 Biosimulation Services Market Size, By Region, 2013–2020 (USD Million)
Table 18 Biosimulation Market Size for In-House Services, By Region, 2013–2020 (USD Million)
Table 19 Biosimulation Market Size for External/Contract Services, By Region, 2013–2020 (USD Million)
Table 20 Biosimulation Market Size, By Application, 2013–2020 (USD Million)
Table 21 Market Size for Biosimulation Drug Development, By Application, 2013–2020 (USD Million )
Table 22 Market Size for Biosimulation Drug Development, By Region, 2013–2020 (USD Million)
Table 23 Market Size for Preclinical Testing, By Application, 2013–2020 (USD Million )
Table 24 Biosimulation Market Size for Preclinical Testing, By Region, 2013–2020 (USD Million )
Table 25 Market Size for PK/PD, By Region, 2013–2020 (USD Million)
Table 26 Market Size for ADME/TOX, By Region, 2013–2020 (USD Million)
Table 27 Biosimulation Market Size for Clinical Trials, By Region, 2013–2020 (USD Million)
Table 28 Market Size for Biosimulation Drug Discovery, By Application, 2013–2020 (USD Million )
Table 29 Biosimulation Market Size for Biosimulation Drug Discovery, By Region, 2013–2020 (USD Million )
Table 30 Market Size for Target Identification and Optimization, By Region, 2013–2020 (USD Million)
Table 31 Market Size for Lead Identification and Optimization, By Region, 2013–2020 (USD Million)
Table 32 Biosimulation Market Size for Other Applications, By Region, 2013–2020 (USD Million )
Table 33 Market Size, By End User, 2013–2020 (USD Million)
Table 34 Market Size for Pharmaceutical and Biotechnology Companies, By Region, 2013–2020 (USD Million)
Table 35 Market Size for Academic and Government Research Institutes, By Region, 2013–2020 (USD Million)
Table 36 Biosimulation Market Size for Cros, By Region, 2013–2020 (USD Million)
Table 37 Biosimulation Market Size for Regulatory Authorities, By Region, 2013–2020 (USD Million)
Table 38 Biosimulation Market Size for Other End Users, By Region, 2013–2020 (USD Million)
Table 39 Biosimulation Market Size, By Region, 2013–2020 (USD Million)
Table 40 North America: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 41 North America: Biosimulation Market Size, By Software, 2013–2020 (USD Million)
Table 42 North America: Market Size, By Service, 2013–2020 (USD Million)
Table 43 North America: Market Size, By Application, 2013–2020 (USD Million)
Table 44 North America: Market Size for Biosimulation Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 45 North America: Market Size for Biosimulation Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 46 North America: Biosimulation Market Size, By End User, 2013–2020 (USD Million)
Table 47 Europe: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 48 Europe: Market Size, By Software, 2013–2020 (USD Million)
Table 49 Europe: Biosimulation Market Size, By Service, 2013–2020 (USD Million)
Table 50 Europe: Biosimulation Market Size, By Application, 2013–2020 (USD Million)
Table 51 Europe: Market Size for Biosimulation Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 52 Europe: Market Size for Biosimulation Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 53 Europe: Biosimulation Market Size, By End User, 2013–2020 (USD Million)
Table 54 Asia: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 55 Asia: Market Size, By Software, 2013–2020 (USD Million)
Table 56 Asia: Market Size, By Service, 2013–2020 (USD Million)
Table 57 Asia: Market Size, By Application, 2013–2020 (USD Million)
Table 58 Asia: Biosimulation Market Size for Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 59 Asia: Biosimulation Market Size for Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 60 Asia: Market Size, By End User, 2013–2020 (USD Million)
Table 61 RoW: Biosimulation Market Size, By Product, 2013–2020 (USD Million)
Table 62 RoW: Biosimulation Market Size, By Software, 2013–2020 (USD Million)
Table 63 RoW: Market Size, By Service, 2013–2020 (USD Million)
Table 64 RoW: Biosimulation Market Size, By Application, 2013–2020 (USD Million)
Table 65 RoW: Market Size for Biosimulation Drug Development Applications, By Type, 2013–2020 (USD Million)
Table 66 RoW: Market Size for Biosimulation Drug Discovery Applications, By Type, 2013–2020 (USD Million)
Table 67 RoW: Market Size, By End User, 2013–2020 (USD Million)
Table 68 Rank of Companies in the Global Market, 2015
Table 69 Market Developments of Biosimulation Between 2013 and 2015
Table 70 Product Upgradation, 2013–2015
Table 71 Agreements, Collaborations, Expansions, and Partnerships, 2013–2015
Table 72 New Product and Service Launches, 2013–2015
Table 73 Acquisitions, 2013–2015
Table 74 Other Developments, 2013–2015
Table 75 Strategic Benchmarking of Market Players of Biosimulation


List of Figures (64 Figures)

Figure 1 Global Biosimulation Market
Figure 2 Research Methodology
Figure 3 Market Size Estimation Methodology: Bottom-Up Approach
Figure 4 Market Size Estimation Methodology: Top-Down Approach
Figure 5 Breakdown of Primary Interviews: By Company Type, Designation, and Region
Figure 6 Data Triangulation Methodology
Figure 7 Biosimulation Market Size, By Product, 2015 vs 2020 (USD Million)
Figure 8 Biosimulation Market Size, By Application, 2015 vs 2020 (USD Million)
Figure 9 Biosimulation Market Size, By End User, 2015 vs 2020 (USD Million)
Figure 10 Biosimulation Market Size, By Region, 2015 vs 2020 (USD Million)
Figure 11 Global Biosimulation Market to Witness High Growth During the Forecast Period
Figure 12 Biosimulation  Software Product Segment to Account for the Largest Market Share in 2015
Figure 13 Europe to Witness Highest Growth Rate From 2015 to 2020
Figure 14 European Market Showcases Lucrative Growth Opportunities of Biosimulation
Figure 15 Biosimulation Market Segmentation: By Product
Figure 16 Biosimulation Market Segmentation: By Application
Figure 17 Biosimulation Market Segmentation: By End User
Figure 18 Growth in the Pharmaceutical and Biotechnology Industries Along With Increase in R&D Investments in These Industries Will Drive the Biosimulation Market
Figure 19 New Pharmaceutical Drug Launches (2003–2013)
Figure 20 Biosimulation Market Segmentation, By Product
Figure 21 Biosimulation Market, By Product, 2015 (USD Million)
Figure 22 Biosimulation Software Market Size, By Type, 2015 vs 2020 (USD Million)
Figure 23 Biosimulation Software Market Size, By Region, 2015 vs 2020 (USD Million)
Figure 24 Biosimulation Services Market Size, By Type, 2013–2020 (USD Million)
Figure 25 Biosimulation Services Market Size, By Region, 2013–2020 (USD Million)
Figure 26 Biosimulation Market Segmentation, By Application
Figure 27 Drug Development Segment to Command the Largest Share of the Biosimulation Market in 2015
Figure 28 Biosimulation Market Size for Drug Development, By Application, 2015 vs 2020 (USD Million )
Figure 29 North America Expected to Be the Largest Regional Segment for Drug Development Applications
Figure 30 Biosimulation Market Size for Preclinical Testing, By Application, 2015 vs 2020 (USD Million)
Figure 31 North America Expected to Be the Largest Regional Segment for Preclinical Testing Applications
Figure 32 Biosimulation Market Size for Drug Discovery, By Application, 2015 vs 2020 (USD Million )
Figure 33 Europe is the Fastest-Growing Regional Segment for Drug Discovery Applications
Figure 34 Other Applications Market in Europe to Witness Highest Growth in the Forecast Period
Figure 35 Biosimulation Market, By End User
Figure 36 Biosimulation Market Size, By End User, 2015 (USD Million)
Figure 37 Number of Biotechnology and Pharmaceutical Patents Granted in 2012, By Region
Figure 38 Pharmaceutical and Biotechnology Companies Segment to Witness Highest Growth in Europe
Figure 39 Public-Sector Research Funding Driving the Growth of the Academic & Government Research Institutes End-User Segment
Figure 40 North America Dominates Market for Academic and Government Research Institutes
Figure 41 North America Expected to Dominate Biosimulation Market for Cros
Figure 42 Europe is Expected to Grow at the Highest Cagr in the Biosimulation Market for Regulatory Authorities
Figure 43 Europe to Witness Highest Growth in the Biosimulation Market for Other End Users in the Forecast Period
Figure 44 Biosimulation Market Segmentation, By Region
Figure 45 North America to Dominate the Global Biosimulation Market in the Forecast Period
Figure 46 Biosimulation Market in Europe to Witness the Highest Growth From 2015 to 2020
Figure 47 North America: Market Snapshot
Figure 48 Biosimulation Software to Command the Largest Share of the Biosimulation Market in North America in 2015
Figure 49 Drug Development Segment to Account for the Largest Share of the Biosimulation Applications Market in North America By 2020
Figure 50 Pharmaceutical and Biotechnology Companies to Form the Largest End-User Segment in North America in 2015
Figure 51 Europe: Market Snapshot
Figure 52 Biosimulation Software to Command the Largest Share of the European Biosimulation Market in 2015
Figure 53 Drug Development Segment to Account for the Largest Share of the Biosimulation Applications Market in Europe By 2020
Figure 54 Pharmaceutical and Biotechnology Companies to Account for the Largest Share of the Biosimulation End-User Market in Europe in 2015
Figure 55 Biosimulation Software to Command the Largest Share of the Biosimulation Market in Asia in 2015
Figure 56 Drug Development Application Segment to Dominate the Biosimulation Market in Asia By 2020
Figure 57 Pharmaceutical and Biotechnology Companies to Account for the Largest Share of the Biosimulation End-User Market in Asia in 2015
Figure 58 Biosimulation Software to Command the Largest Share of the RoW Biosimulation Market in 2015
Figure 59 Drug Development Application Segment to Command the Largest Share of the Biosimulation Market in the RoW Region By 2020
Figure 60 Pharmaceutical and Biotechnology Companies End-User Segment to Dominate the RoW Market for Biosimulation in 2015
Figure 61 Key Developments in the Biosimulation Market, 2013-2015
Figure 62 Company Snapshot: Simulation Plus Inc.
Figure 63 Company Snapshot: Dassault Systθmes SA
Figure 64 Company Snapshot: Physiomics PLC

The biosimulation market is expected to reach USD 2,107.99 Million by 2020 from USD 1,034.93 Million in 2015, growing at a CAGR of 15.29% between 2015 and 2020. A strong trend of R&D investments in biotechnology and pharmaceutical industries will majorly drive the growth of the market. Other growth factors include the need to curtail drug discovery & development costs, growth in the biologics and biosimilars markets, the increased use of personalized medicines, technological advancements, and periodic product upgradation. The increased applications of biosimulation in the defense, industrial bioprocessing, nutraceuticals, and agri-food production will provide opportunities for market growth.

This report segments the global biosimulation market by product, application, and end user. The global market product segments are software and services. The software segment is further classified into molecular modeling and simulation software, PBPK modeling and simulation software, PK/PD modeling and simulation software, trail design software, toxicity prediction software, and other software (QSP, visualizing and analytical software). The services segment includes into in-house services and external/contract services. In 2015, the software segment is expected to account for the largest share of the global biosimulation market.

The application segments of this market are drug discovery, drug development, and other applications. The drug development application segment is further classified into preclinical testing and clinical trials. The drug discovery segment is divided into target identification & validation and lead identification & optimization. In 2015, drug development is expected to account for the largest share of the global market.

On the basis of end users, the global biosimulation market report is segmented into academic and government research institutes, pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, and other end users. In 2015, the pharmaceutical and biotechnology companies segment is expected to account for the largest share of the global market.

The geographic segments included in this report are North America, Europe, Asia, and the Rest of the World (RoW). In 2015, the North America is expected to command the largest share of the global biosimulation market. Europe is expected to register the highest growth due to increasing government funding and the large number of pharmaceuticals and biotechnology companies in this region.

Major players in the global biosimulation market are Certara USA, Inc. (U.S.), Simulation Plus Inc. (U.S.), Dassault Systθmes SA (France), Schrφdinger Inc. (U.S.), Advanced Chemistry Development, Inc. (Canada), Chemical Computing Group, Inc. (Canada), Physiomics PLC (U.K.), Entelos Holding Corporation (U.S.), Rhenovia Pharma Ltd. (France), and Genedata AG (Switzerland).

Biosimulation Market

Biosimulation Market

Biosimulation Market

Biosimulation Market

Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Please visit http://www.marketsandmarkets.com/knowledge-process-outsourcing-services.asp to specify your custom Research Requirement

Connect With Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441
UK : 44-800-368-9399

Search reports